Review Article
Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule
| Lp(a) should be measured once in all subjects at intermediate or high risk of CVD/CHD who present with one of the following: | (i) Premature CVD | (ii) Recurrent CVD despite statin treatment | (iii) Familial hypercholesterolemia | (iv) Strong family history of premature CVD and/or elevated Lp(a) ≥500 mg/L | (v) Recurrent CVD despite optimal lipid-lowering treatment | (vi) ≥5% 10-year risk of fetal CVD according to European guidelines | (vii) ≥10% 10-year risk of fetal CVD according to US guidelines | (viii) 10–19% Framingham risk according to the 2012 Canadian Cardiovascular Society recommendations | Repeat measurement is only necessary if treatment for high Lp(a) levels is initiated in order to evaluate therapeutic response |
|
|
This table was adopted from [ 194]. |